Public trial registry of the CCC-Munich

Trial AIO-STO-0217 - INTEGA

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
AIO-STO-0217 - INTEGA
World
Full title
:

Ipilimumab in Kombination mit Nivolumab und Trastuzumab bei bisher unbehandelten HER2 positiven Patienten mit lokal fortgeschrittenem oder metastasiertem EsophagoGastric Adenokarzinom Die randomisierte Phase 2 INTEGA Studie. 05.03.2022 das offizielle Studienende!

World
NCT number
:
World
Responsible organization
:
3. Med 3. Med Ismaninger Str. 22 81675 München Germany
Indications
Classification Code Description
- Esophageal cancer
Trial design
World
Phase
:
II
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Positive
World
Institutional review board - vote date
:
2018-03-01
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy
:

Zielgerichtet

Participants
Function Prename Surname Organization
World Responsible contact Sylvie Lorenzen 3. Med 3. Med Ismaninger Str. 22 81675 München Germany Magnifier